Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Hyperuricemia 2Tumor Lysis Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 60Vincristine 57Doxorubicin 54Rituximab 48Prednisone 44Etoposide 35Radiotherapy 34Cytarabine 26Filgrastim 22Methotrexate 21Bleomycin 21Dexamethasone 18Peripheral Blood Stem Cell Transplantation 14Carmustine 14Vinblastine 13Prednisolone 13VAP-cyclo protocol 12Melphalan 12Mitoxantrone 11Mercaptopurine 10Leucovorin 10Dacarbazine 9Ifosfamide 8Granulocyte Colony-Stimulating Factor 8Procarbazine 7Methylprednisolone 7Lenalidomide 7Gemcitabine 7Daunorubicin 7Cisplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma × rasburicase × Clear all
NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡